A tumor-selective, safe therapeutic gene cassette specifically activated by NF-κB to produce cytokine IL-15 and microRNAs silencing two key immune checkpoints, PD-L1 and CD47, is constructed and shows significant antitumor effects, favorable tumor selectivity, and biosafety across multiple murine solid tumor models.
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of several hematological malignancies, but its broader application remains constrained by the complexity, cost, and time required for conventional ex vivo manufacturing. In vivo CAR T-cell therapy has emerged as a promising next-generation str...
Next-generation engineering strategies are being designed to overcome the obstacles that constrain CAR-T-cell efficacy in solid tumors and to guide the development of safer and more effective therapeutic platforms.
Zi-Yan Kong, Jin-Ke Wang· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
